Airfinity US RSV vaccine market estimate cut by 64% from $4.7bn to $1.7bn a year by 2030 following recommendations for single lifetime shot for elderly people
24. Juli 2024 02:00 ET
|
Airfinity
London, England, July 24, 2024 (GLOBE NEWSWIRE) -- Airfinity has reduced its sales projections for vaccines against Respiratory Syncytial Virus (RSV) for older adults in the US from $4.7bn per year...
Respiratory Syncytial Virus Therapeutics Market to Rise at a 14.6% CAGR from 2023 to 2031, Reaching a Value of USD 3.8 billion | Exclusive Report by Transparency Market Research, Inc.
13. Februar 2024 11:55 ET
|
Transparency Market Research
Wilmington, Delaware, United States, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The respiratory syncytial virus (RSV) therapeutics market was valued at US$ 1.1 billion in...
Icosavax, Inc. Announces Agreement to be Acquired by AstraZeneca
12. Dezember 2023 02:05 ET
|
Icosavax, Inc.
Icosavax, Inc. Announces Agreement to be Acquired by AstraZeneca
Icosavax Announces Positive Topline Interim Phase 2 Results for Combination VLP Vaccine Candidate IVX-A12 Against RSV and hMPV in Older Adults
12. Dezember 2023 02:00 ET
|
Icosavax, Inc.
Icosavax Announces Positive Topline Interim Phase 2 Results for Combination VLP Vaccine Candidate IVX-A12 Against RSV and hMPV in Older Adults
Icosavax Reports Second Quarter 2023 Financial Results and Provides Corporate Update
14. August 2023 16:05 ET
|
Icosavax, Inc.
- Positive topline interim Phase 1 results for bivalent VLP vaccine candidate IVX-A12 against RSV and hMPV in older adults - - Positive twelve-month immunogenicity data and initial proof-of-concept...
Respiratory Syncytial Virus Market Surges Amid Global Health Concerns: Key Players, Size, Share, Product, Method, Region and Growth Forecast
01. August 2023 09:02 ET
|
Delvens
New York, Aug. 01, 2023 (GLOBE NEWSWIRE) -- According to a new market research report titled, "Respiratory Syncytial Virus Market is Segmented by Product (Kits and Reagents, Instruments, and...
Icosavax Announces $67.8 Million Registered Direct Offering of Common Stock
22. Mai 2023 17:53 ET
|
Icosavax, Inc.
SEATTLE, May 22, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines...
Icosavax Announces Positive Topline Interim Phase 1 Results for Bivalent VLP Vaccine Candidate IVX-A12 Against RSV and hMPV in Older Adults
22. Mai 2023 17:37 ET
|
Icosavax, Inc.
– IVX-A12 induced robust immune responses at Day 28 to both RSV and hMPV in older adults – – IVX-A12 was generally well tolerated with no vaccine-related SAEs – – First demonstration of hMPV...
ProLectin-M Demonstrates Significant Activity Against Influenza and Respiratory Syncytial Virus
28. Februar 2023 08:00 ET
|
BIOXYTRAN, INC.
Activity in Influenza and Respiratory Syncytial Virus highlights the broad- spectrum antiviral potential of ProLectin-M BOSTON, MASSACHUSETTS, Feb. 28, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC....
Icosavax Granted FDA Fast Track Designation for IVX-A12
21. Februar 2023 08:00 ET
|
Icosavax, Inc.
SEATTLE, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines...